These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21948622)

  • 1. Commentary on "incidence and nature of testicular toxicity findings…".
    Boekelheide K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):501-3. PubMed ID: 21948622
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on incidence and nature of testicular toxicity findings in pharmaceutical development survey: a pathologist's perspective.
    Creasy DM
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):508-10. PubMed ID: 21818841
    [No Abstract]   [Full Text] [Related]  

  • 3. Whither the resolution of testicular toxicity?
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):504-7. PubMed ID: 21770029
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence and nature of testicular toxicity findings in pharmaceutical development.
    Sasaki JC; Chapin RE; Hall DG; Breslin W; Moffit J; Saldutti L; Enright B; Seger M; Jarvi K; Hixon M; Mitchard T; Kim JH
    Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):511-25. PubMed ID: 22162370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 6. Single dose toxicity and repeated dose toxicity studies: introductory remarks.
    Kurokawa Y; Matsuzawa T
    J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of emerging toxicity screens in drug discovery: challenges and implications.
    Wilson AG; Liu X; Kramer JA
    Future Med Chem; 2009 Oct; 1(7):1201-5. PubMed ID: 21426096
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolomics in toxicology: preclinical and clinical applications.
    Robertson DG; Watkins PB; Reily MD
    Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 10. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
    Kroll F; Dreger M
    Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
    [No Abstract]   [Full Text] [Related]  

  • 11. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to special issue on developmental and reproductive toxicity study designs for pharmaceuticals.
    Wise LD
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):417. PubMed ID: 20025037
    [No Abstract]   [Full Text] [Related]  

  • 19. What have we learned from pre-clinical juvenile toxicity studies?
    Bailey GP; Mariën D
    Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.